MDM2 and neoplasm: ERBB4 is rarely mutated in human cancers [51] but recently it was shown that ERBB4 can inhibit the tumor suppressor TP53 by regulating the MDMX-MDM2 complex stability, the primary inhibitors of TP53, leading to TP53 inactivation in tumor [52].